Abstract: A method of treating a hematological malignancy associated with an altered RUNX1 activity or expression is disclosed. The method comprising administering to a subject in need thereof a therapeutically effective amount of an agent which directly downregulates an activity or expression of RUNX1, thereby treating the hematological malignancy associated with the altered RUNX1 activity or expression.

Abstract: The invention discloses a knockout mouse that is homozygous for a RUNX3 null allele, as a novel model for chronic inflammatory disease. The present invention provides methods of diagnosing and assessing predisposition to chronic inflammatory diseases. The present invention further provides methods for testing agents for effectiveness in treating and/or preventing diseases associated with chronic inflammatory or autoimmune conditions.

Abstract: The invention discloses a knockout mouse that is homozygous for a RUNX3 null allele, as a novel model for chronic inflammatory disease. The present invention provides methods for treating T cell-related inflammatory conditions by cell therapy, gene therapy or antisense for up regulating or down regulating RUNX3. The invention further relates to methods of diagnosing and assessing predisposition to chronic inflammatory diseases. The present invention further provides methods for testing agents for effectiveness in treating and/or preventing diseases associated with chronic inflammatory or autoimmune conditions.

Abstract: Amyloid precursor protein and non-glycosylated peptides derived therefrom especially from the A&bgr; domain of amyloid precursor protein are useful in prevention or treatment of cancer, and for immunostimulation in individuals with compromised immune systems. A peptide comprising residues 1-42 of the amyloid precursor protein, as well as smaller fragments and analogs of this peptide, which demonstrate the anti-cancer activity, are disclosed. A peptide comprising residues 1-16 of the amyloid precursor protein is one currently preferred active fragment. Pharmaceutical compositions comprising these peptides, and methods of using them to prevent or inhibit tumor growth and metastases are disclosed. Methods of gene therapy using APP or APP-derived peptides are also disclosed for treatment of cancer and for immunostimulation.

Abstract: A double-stranded cDNA molecule which includes DNA encoding human cytoplasmic superoxide dismutase has been created. The sequence of one strand of a double-stranded DNA molecule which encodes human cytoplasmic superoxide dismutase has been discovered. Such molecules may be introduced in procaryotic, e.g., bacterial, or eucaryotic, e.g., yeast or mammalian, cells and the resulting cells cultured or grown under suitable conditions so as to produce human cytoplasmic superoxide dismutase which may then be recovered.

Abstract: A double-stranded cDNA molecule which includes DNA encoding human cytoplasmic superoxide dismutase has been created. The sequence of one strand of a double-stranded DNA molecule which encodes human cytoplasmic superoxide dismutase has been discovered. Such molecules may be introduced in procaryotic, e.g., bacterial, or eucaryotic, e.g., yeast or mammalian, cells and the resulting cells cultured or grown under suitable conditions so as to produce human cytoplasmic superoxide dismutase which may then be recovered.